Cyclic aryl hydroxamic acids, derivatives thereof and method of use as
申请人:E. R. Squibb & Sons, Inc.
公开号:US04757078A1
公开(公告)日:1988-07-12
Cyclic aryl hydroxamic acids and derivatives thereof are provided having the structure ##STR1## wherein R is H or arylalkyl, and including acid-addition salts thereof. These compounds are useful as inhibitors of leukotriene production and as such are useful as antiallergy, anti-inflammatory and anti-psoriatic agents.
NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES
申请人:Bar Thomas
公开号:US20110065734A1
公开(公告)日:2011-03-17
The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth.
Sunlight‐ or UVA‐Light‐Mediated Synthesis of Hydroxamic Acids from Carboxylic Acids
作者:Olga G. Mountanea、Christiana Mantzourani、Maroula G. Kokotou、Christoforos G. Kokotos、George Kokotos
DOI:10.1002/ejoc.202300046
日期:——
A sunlight- or UVA-light-mediated synthesis of hydroxamicacids from carboxylic acids and protected hydroxylamines is reported, the key step of which is the formation of a charge transfer complex. Mechanistic studies by DI-HRMS provide experimental evidence for the formation of various intermediates. Two hydroxamic drugs (Vorinostat and Bufexamac) were synthesized.
Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
申请人:4SC AG
公开号:EP2060565A1
公开(公告)日:2009-05-20
The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates
A-L-B (I)
wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth.
本发明涉及式 I 的双官能团化合物或其药学上可接受的盐或溶解物
A-L-B (I)
其中 A 是组蛋白去乙酰化酶(HDAC)抑制分子,L 是单键或连接基团,B 是蛋白激酶抑制分子。根据式(I)的双功能化合物可用于治疗恶性和非恶性肿瘤以及与细胞异常生长有关的疾病。